Storia in 2 fonti

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk.

Raccontata da

endpoints.news

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo4 g fa

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk.

originale

fiercepharma.com3 g fa

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed a phase 3 flop in the KRAS G12C inhibitor’s smaller-op | As Bristol Myers…

Leggi questa versione → originale

Timeline cronologica

lunedì 6 luglio 2026·endpoints.news
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk.
martedì 7 luglio 2026·fiercepharma.com
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed a phase 3 flop in the KRAS G12C…